Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation

Quinn, Julian M. W., Horwood, Nicole J. ORCID: https://orcid.org/0000-0002-6344-1677, Elliott, Jan, Gillespie, Matthew T. and Martin, T. John (2000) Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation. Journal of Bone and Mineral Research, 15 (8). pp. 1459-1466. ISSN 0884-0431

Full text not available from this repository. (Request a copy)

Abstract

Osteoclast formation in bone is supported by osteoblasts expressing receptor activator of NF-kappa B ligand (RANKL) and macrophage colony-stimulating factor (M-CSF) expression. Numerous osteotropic factors regulate expression levels of RANKL and the RANKL decoy receptor osteoprotegerin (OPG) in osteoblasts, thereby affecting osteoclast differentiation. However, not only in RANKL widely expressed in soft tissues, but osteoclasts have been noted in extraskeletal lesions. We found that cultured skin fibroblastic cells express RANKL, M-CSF, and OPG messenger (mRNA). Stimulation by 1 alpha,25 dihydroxyvitamin D3 [1,25(OH)2D3] plus dexamethasone (Dex) augmented RANKL and diminished OPG mRNA expression in fibroblastic cells and caused the formation of numerous osteoclasts in cocultures of skin fibroblastic cells with hemopoietic cells or monocytes. The osteoclasts thus formed expressed tartrate-resistant acid phosphatase (TRAP) and calcitonin (CT) receptors and formed resorption pits in cortical bone. Osteoclast formation also was stimulated (in the presence of Dex) by prostaglandin E2 (PGE2), interleukin-11 (IL-11), IL-1, tumor necrosis factor-alpha (TNF-alpha), and parathyroid hormone-related protein (PTHrP), factors which also stimulate osteoclast formation supported by osteoblasts. In addition, granulocyte-macrophage-CSF (GM-CSF), transforming growth factor-beta (TGF-beta), and OPG inhibited osteoclast formation in skin fibroblastic cell-hemopoietic cell cocultures; CT reduced only osteoclast nuclearity. Fibroblastic stromal cells from other tissues (lung, respiratory diaphragm, spleen, and tumor) also supported osteoclast formation. Thus, RANKL-positive fibroblastic cells in extraskeletal tissues can support osteoclastogenesis if osteolytic factors and osteoclast precursors are present. Such mesenchymally derived cells may play a role in pathological osteolysis and may be involved in osteoclast formation in extraskeletal tissues.

Item Type:	Article
Uncontrolled Keywords:	animals,pharmacology,genetics,cell differentiation,cells, cultured,coculture techniques,pharmacology,metabolism,gene expression,genetics,ligands,genetics,genetics,mice,metabolism,cytology,cytology,osteoprotegerin,rank ligand,receptor activator of nuclear factor-kappa b,genetics,receptors, tumor necrosis factor,drug effects
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups:	Faculty of Medicine and Health Sciences > Research Centres > Metabolic Health
Depositing User:	LivePure Connector
Date Deposited:	06 Mar 2019 09:30
Last Modified:	25 Sep 2024 13:57
URI:	https://ueaeprints.uea.ac.uk/id/eprint/70119
DOI:	10.1359/jbmr.2000.15.8.1459

Actions (login required)

View Item